Cargando…
IMT-01 THERAPEUTIC EFFECT AGAINST LOWER GRADE GLIOMA INDUCED BY DENDRITIC CELL BASED IMMUNOTHERAPY
BACKGROUND: This trial was designed to evaluate the safety and clinical responses to an immunotherapy with fusions of dendritic and glioma cells in patients with lower grade glioma (LGG; WHO grade II-III glioma). METHOD: Autologous cultured glioma cells obtained from surgical specimens were fused wi...
Autores principales: | Akasaki, Yasuharu, Takei, Jun, Kamata, Yuko, Yamamoto, Yohei, Mori, Ryosuke, Tanaka, Toshihide, Yanagisawa, Takaaki, Murayama, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213172/ http://dx.doi.org/10.1093/noajnl/vdz039.076 |
Ejemplares similares
-
IMT-1 PROS AND CONS OF SURGICAL INTERVENTION FOR DIFFUSE MIDLINE GLIOMA AIMED AT DENDRITIC CELL IMMUNOTHERAPY
por: Akasaki, Yasuharu, et al.
Publicado: (2022) -
IMT-1 A translational research for practical use of dendritic cell-based immunotherapy against malignant glioma
por: Akasaki, Yasuharu, et al.
Publicado: (2021) -
COT-08 Analysis of prognosis of biopsy/partial resection cases of malignant glioma
por: Yamamoto, Yohei, et al.
Publicado: (2020) -
PEDT-03 A clinical trial of dendritic cell-based immunotherapy for refractory brain tumors in children
por: Akasaki, Yasuharu, et al.
Publicado: (2020) -
Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
por: Takei, Jun, et al.
Publicado: (2023)